imshealthchinaFebruary 28, 2018
Tag: china , hospital pharmaceutical market
Overall market performance
According to statistics, the total sales* of China’s hospital pharmaceutical market were RMB 187.2 billion in 2017 Q2, growing by 4.3% year on year. Based on 12-month MAT (Moving Annual Total*), the MAT growth of 2017 Q2 was 6.3%.
*Sales: Purchase amount of hospital pharmacies
* MAT (Moving Annual Total): The total of figures over the course of the previous 12 months from a designated time node. It means the sales over the course from 2016 Q3 to 2017 Q2 here.
(Data source: China hospital drug statistical report of IMS, >=100 beds)
Market performance of multinational enterprises and Chinese enterprises
The 2017 Q2 sales growth of multinational enterprises was 9.4% in China, flat with the same period of last year, while that of Chinese enterprises was 2.7%, clearly down than the same period of last year. Pfizer, Yangtze River and AstraZeneca separately ranked the top three in enterprise quarterly sales rankings.
From the perspective of cities, the MAT growth of multinational enterprises and Chinese enterprises was separately 7.4% and 8.5% in first-tier cities, while the MAT growth thereof was separately 12.7% and 6.7% in small and medium-sized cities.
First-tier cities: Beijing, Shanghai, and Guangzhou
Market performance of key therapeutic areas and major products
From the perspective of therapeutic areas, antineoplastic drugs and immunomodulators, and respiratory system drugs maintained some growth in this quarter, while the growth of Chinese patent medicines and anti-infectives continued to slow down due to use restriction of adjuvant drugs and further strengthening of antibiotic drug clinical application management, etc.
From the perspective of products, the multinational enterprise’s Lipitor ranked top in the 2017 Q2 product sales rankings, the Chinese enterprise’s Jialuoning ranked second, and Plavix ranked third. From the perspective of MAT growth, Jialuoning and Sulperazon separately reached 29.3% and 28.4%, while other products fluctuated in terms of the growth, but did not change much in the rankings.
Top 10 Hospital Pharmaceutical Product Suppliers in China in 2017 Q2 (by Quarterly Sales)
Ranking |
Company |
MAT growth, % |
1 |
Pfizer |
13.8% |
2 |
Yangtze River Pharmaceutical |
13.8% |
3 |
AstraZeneca |
12.0% |
4 |
Qilu Pharmaceutical |
5.3% |
5 |
Hengrui Medicine |
17.6% |
6 |
Sanofi |
10.2% |
7 |
Sihuan Pharm |
5.4% |
8 |
Fosun Pharmaceutical |
4.6% |
9 |
Chiatai Tianqing |
10.5% |
10 |
Bayer |
9.8% |
Top 10 Therapeutic Areas in Hospital Drug Use in 2017 Q2 (by Quarterly Sales)
Ranking |
Therapeutic area |
MAT growth, % |
1 |
Others (mainly the Chinese patent medicines) |
2.5% |
2 |
Anti-infectives for systemic use |
3.3% |
3 |
Digestive tract and metabolism drugs |
6.6% |
4 |
Cardiovascular system drugs |
7.6% |
5 |
Antineoplastic drugs and immunomodulators |
9.7% |
6 |
Central nervous system drugs |
9.2% |
7 |
Medical solutions |
3.6% |
8 |
Blood and blood-forming organ drugs |
11.2% |
9 |
Respiratory system drugs |
9.8% |
10 |
Musculoskeletal system drugs |
6.9% |
Data source: IMS CHPA (China hospital drug statistical report), >=100 beds
Top 10 Products in Hospital Drug Use in 2017 Q2 (by Quarterly Sales)
Ranking |
Product name |
Manufacturer |
MAT growth, % |
1 |
Lipitor |
Pfizer |
13.6% |
2 |
Jialuoning |
Yangtze River Pharmaceutical |
29.3% |
3 |
Plavix |
Sanofi |
10.4% |
4 |
Beitong |
Shandong Danhong |
9.2% |
5 |
Xueshuantong |
Guangxi Wuzhou Pharmaceutical |
-2.4% |
6 |
Pulmicort Respules |
AstraZeneca |
19% |
7 |
Shenjie |
Qilu Pharmaceutical |
-9.8% |
8 |
Sulperazon |
Pfizer |
28.4% |
9 |
Salvianolate Injection |
Shanghai Green Valley Pharmaceutical |
0.7% |
10 |
Aodejin |
Jinzhou Ahon Pharmaceutical |
-5.4% |
Data source: IMS CHPA (China hospital drug statistical report), >=100 beds
Also read: Review of Drug Use on Hospital Market in China in 2017 Q3
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: